Sentinel node biopsy in patients with previous breast aesthetic surgery

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Sentinel lymph node biopsy (SLNB) is the standard for axillary staging in early breast cancer.
• Previous aesthetic breast surgery was considered a contraindication for SLNB due to insufficient data.
• This study addresses the safety and efficacy of SLNB in patients with a history of cosmetic breast surgery.

Purpose of the Study:

• To evaluate the feasibility and outcomes of SLNB in early breast cancer patients with prior aesthetic breast surgery.
• To determine if previous breast augmentation or reduction mammoplasty impacts SLNB success rates.
• To assess the oncologic safety of SLNB in this patient population.

Main Methods:

• A cohort of 70 patients with prior aesthetic breast surgery (50 augmentation, 20 reduction) underwent SLNB.
• All patients received lymphoscintigraphy with 99Tc for sentinel node identification.
• SLNB was performed as part of either conservative breast surgery or mastectomy.

Main Results:

• The sentinel node identification rate was 100% across all patients.
• SLN positivity was observed in 32% of patients (18 macrometastasis, 7 micrometastasis).
• No axillary recurrences were noted during a median follow-up of 19 months.

Conclusions:

• A history of breast augmentation or reduction mammoplasty is not a contraindication for performing SLNB.
• SLNB is a safe and effective technique for axillary staging in early breast cancer patients with prior aesthetic surgery.
• These findings support the routine use of SLNB in this patient group.